Breast Cancer Trial of RPR109881 Versus Capecitabine in Male or Female Patients With Advanced Breast Cancer

Key facts

Sponsor

Sanofi

Principal Investigator

ICD CSD

Sanofi

Intervention

larotaxel (RPR109881, XRP9881)(drug)

Enrollment

438 target

Eligibility

18 years · All sexes

Timeline

2004 – 2006

Study locations (30)

• Birmingham, Alabama, United States
• Tucson, Arizona, United States
• Little Rock, Arkansas, United States
• Bakersfield, California, United States
• Burbank, California, United States
• Concord, California, United States
• Fountain Valley, California, United States
• Fresno, California, United States
• Fullerton, California, United States
• Gilroy, California, United States
• Long Beach, California, United States
• Los Angeles, California, United States
• Monterey Park, California, United States
• Northridge, California, United States
• Oxnard, California, United States
• +15 more locations on ClinicalTrials.gov

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Body integrity dysphoria

Additional recruiting or active studies for the same condition.

• RECRUITINGNANCT06898905
  Hyperfractionated Dual Equivalent Fractionated Radiation Therapy
  Yale University
• RECRUITINGPHASE1NCT06966388
  Study to Evaluate the Feasibility of Twice Daily Use of Topical Azelaic Acid in Breast Cancer Patients Undergoing Radiation
  Virginia Commonwealth University
• RECRUITINGPHASE1, PHASE2NCT06853015
  Double Dose 4-AP on Functional Recovery After Spinal Cord Injury
  Shirley Ryan AbilityLab
• ACTIVE NOT RECRUITINGPHASE3NCT05456425
  A Clinical Trial on Safety and Efficacy of CBT-001 in Patients With Pterygium
  Cloudbreak Therapeutics, LLC

See all trials for Body integrity dysphoria →